title: The safety of testosterone therapy in women.
abstract: Hypoactive sexual desire disorder (HSDD), a subset of female sexual dysfunction, causes personal distress for surgically and naturally postmenopausal and premenopausal women. HSDD has a multi-factorial etiology, including psychosocial factors such as relationship issues and medical factors such as medications, chronic illnesses, and hormonal effects. Although no androgen therapies for female sexual dysfunction are currently approved for use in Canada, clinical trials support the efficacy and short-term safety of testosterone therapy for HSDD. We review the scientific evidence for the safety of testosterone therapy for HSDD.
authors.affiliation: University of Toronto, Toronto ON.
authors.forename: Lina
authors.initials: L
authors.lastname: Al-Imari
authors.affiliation: Department of Obstetrics and Gynecology, University of Toronto, Toronto ON.
authors.forename: Wendy L
authors.initials: WL
authors.lastname: Wolfman
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000139:chemically induced; D002170:Canada; D002318:Cardiovascular Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D016889:Endometrial Neoplasms / Q000139:chemically induced; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D013739:Testosterone / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D008055:Lipids; D013739:Testosterone